This activity is expired and is no longer available for CME credit.


Immune Checkpoint Inhibitors for Bladder Cancer: Practice Essential for Community Oncologists and Advanced Practice Providers

Author(s)/Faculty: Daniel G. Chong, MD; Mark T. Fleming, MD
Release Date: 2/23/2018Expiration Date: 2/23/2019
Credit Type: CME / CNE / CPENumber of Credits: 0
Content Type: LectureProvider:
For many years, the mainstay of initial treatment for metastatic bladder cancer has been chemotherapy. However, immunotherapy with PD-1/PD-L1 checkpoint inhibitors is revolutionizing the treatment of bladder cancer. Currently, 5 checkpoint inhibitors are approved for patients who have failed prior platinum-based chemotherapy or are ineligible for cisplatin-based chemotherapy. In this CME activity, expert faculty will assess the clinical evidence regarding the efficacy, safety, and tolerability of checkpoint inhibitors, as well as discuss the benefits and limitations of traditional treatment options. Participants will gain an understanding of the potential impact of checkpoint inhibitors on the treatment of bladder cancer and will learn how to incorporate checkpoint inhibitor-based therapy into their clinical practice through a discussion of case studies.